קלופידקסל 75 - Clopidexcel 75
× ×ª×× × ×ª×¨×פ×
××רש×
| ק×××¦× ×¤×¨×ק×××××ת (ATC4)
|
B01AC
Platelet aggregation inhibitors excluding heparin
|
| ×ר××× ×¤×¢×× (ATC5)
|
Â
|
| צ×רת ×ת×
|
פ××× - PER OS
|
| צ×רת ××× ××
|
×××××ת ×צ×פ×ת פ×××, FILM COATED TABLETS
××× ×עת ××× ×× ×תר ×× ×רע×× ×ש ××××× ×ת ×תר××¤× ××ת×× ×××× ×× ××××××¥ ××¤× ×©××פ××¢ ××¢××× ×צר××
|
| ×ת××××
|
Prevention of atherotrobmotic eventsClopidogrel is indicated in :⢠Adult Patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.⢠Adult Patients suffering from Acute Coronary Syndrome- Non-ST segment elevation acute coronary syndrome (unstable angina/non-Q-wave myocardial infarction (MI)), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA). - ST segment elevation acute myocardial infarction, in combination with ASA in medically treated patients eligible for thrombolytic therapyPrevention of atherotrobmotic and thromboembolic events in atrial fibrillation: In adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for the treatment with Vitamin K antagonists (VKA) Anti-Thrombin or Anti Factor Xa, and who have a low bleeding risk, clopidogrel is indicated in combination with ASA for the prevention of atherothrombotic and thromboembolic events, including stroke.
|
× ×ª×× × ×¡× [ ×צ×× ]
×××××ת ×ס×
- תר××¤× ×××××ת ×ר×ש×× ×¢'× ×¨××¤× ××××× ×× ××××× ××רת
|
×ת×××× ×ס×
-
|
ש×××ש ×ס×
-
|
ת×ר×× ××××× ×ס×
- 01/01/2000
|
| ×ס×רת ××××× ×ס×
×תר××¤× ×××××¨× ×ª×× ×ª× ×××פ×× ×× ××¢×ª× ×©× ××ר××¢×× ××ס××××× ×××תק××× ××× ××ª× ××× ×××: 1. ×××××¤× ××× × ×××× ××שת×ש ××ספ×ר×× ××©× ×¨××ש×ת ×תר ×× ×× ××ר××ת × ×× ××רת. 2. ×××××¤× ×¤××ª× ×ª×פע×ת ××××× ×××פ×× ××ספ×ר××. 3. ×××ר ×¦× ×ª×ר ×× ××פ×××, ×××©× ×©×××©× ××××©× ××פ××. 4. ×××ר ×¦× ×ª×ר ×× ××פ××× ×ת××× ×צ××¤× ×ª×¨××¤× (Drug eluting stent) ×××©× 12 ××××©× ××פ××. 5. ×××ר ×¦× ×ª×ר ×× ××פ××× ×ת××× ×× ×צ××¤× ×ª×¨××¤× (Bare metal stent) ×××©× 9 ××××©× ××פ×× 6. ××××× ×©××§× ×ש××¥ ××××. 7. ××פ×× × ××× ×§×¨××©× ×××©× 12 ××××©× ××פ××, ×××××× ×ס××××× ×תס××× ×ª ×××××ת ××× (Acute coronary syndrome) ש×× × ××ª× ××צע ××× ×¦× ×ª×ר ××××× ××פ××× ×× ×©××××ª× ××× × × ××ª× ×ª ×××פ×× ×¢"× ×¦× ×ª×ר ××××× ××פ×××.
|
|
| ×¢××× ×ר××¤× ××××ר×ת ××¢×××
|
××× ×¢××× ×ר×פ×
Â
|
ת×ר×× ×¢××××: 14/05/19
DEXCEL
ק××פ×××§×¡× - Clopidexcel
true
× ×ª×× × ×¡× [ ×צ×× ]
×××××ת ×ס×
- תר××¤× ×××××ת ×ר×ש×× ×¢'× ×¨××¤× ××××× ×× ××××× ××רת
|
×ת×××× ×ס×
-
|
ש×××ש ×ס×
-
|
ת×ר×× ××××× ×ס×
- 01/01/2000
|
| ×ס×רת ××××× ×ס×
×תר××¤× ×××××¨× ×ª×× ×ª× ×××פ×× ×× ××¢×ª× ×©× ××ר××¢×× ××ס××××× ×××תק××× ××× ××ª× ××× ×××: 1. ×××××¤× ××× × ×××× ××שת×ש ××ספ×ר×× ××©× ×¨××ש×ת ×תר ×× ×× ××ר××ת × ×× ××רת. 2. ×××××¤× ×¤××ª× ×ª×פע×ת ××××× ×××פ×× ××ספ×ר××. 3. ×××ר ×¦× ×ª×ר ×× ××פ×××, ×××©× ×©×××©× ××××©× ××פ××. 4. ×××ר ×¦× ×ª×ר ×× ××פ××× ×ת××× ×צ××¤× ×ª×¨××¤× (Drug eluting stent) ×××©× 12 ××××©× ××פ××. 5. ×××ר ×¦× ×ª×ר ×× ××פ××× ×ת××× ×× ×צ××¤× ×ª×¨××¤× (Bare metal stent) ×××©× 9 ××××©× ××פ×× 6. ××××× ×©××§× ×ש××¥ ××××. 7. ××פ×× × ××× ×§×¨××©× ×××©× 12 ××××©× ××פ××, ×××××× ×ס××××× ×תס××× ×ª ×××××ת ××× (Acute coronary syndrome) ש×× × ××ª× ××צע ××× ×¦× ×ª×ר ××××× ××פ××× ×× ×©××××ª× ××× × × ××ª× ×ª ×××פ×× ×¢"× ×¦× ×ª×ר ××××× ××פ×××.
|
↑חזרה לקטע הקודםהשינוי האחרון נעשה בֹ־2 בפברואר 2014 ב־10:08
